The EBITDA margin was 80bp higher v/s pre-COVID levels, highlighting sustainable cost optimization during the pandemic period. Given the return of COVID-led lockdown, we cut our revenue/PAT estimates by 17%/21% for FY22, but largely maintain our FY23E estimates, factoring in a 23% revenue/PAT CAGR over FY2023E. Maintain Neutral....